Related Experiment Videos

Leukemia inhibitory factor as a mediator of JAK/STAT activation in murine osteoblasts

C Lowe1, G A Gillespie, J W Pike

  • 1Ligand Pharmaceuticals Inc., San Diego, California, USA.

Insights

Leukemia inhibitory factor (LIF) activates bone remodeling by phosphorylating Janus kinases (JAKs) and signal transducers and activators of transcription (STATs). This pathway involves JAK1, JAK2, STAT1, and STAT3, influencing DNA binding in osteoblasts.

Area of Science:

  • Cellular signaling pathways
  • Molecular biology
  • Bone biology

Background:

  • Cytokines mediate cellular effects through signaling cascades.
  • Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are key components of these pathways.
  • Leukemia inhibitory factor (LIF) is implicated in bone remodeling.

Purpose of the Study:

  • To investigate the involvement of JAK/STAT pathway members in mediating LIF actions in osteoblasts.
  • To identify specific JAK and STAT proteins activated by LIF in bone cells.

Main Methods:

  • Utilized MC3T3-E1 cells (osteoblast cell line) and normal murine calvarial osteoblasts.
  • Stimulated cells with LIF and analyzed protein phosphorylation.
  • Employed gel mobility shift assays to assess DNA binding activity of STAT proteins.

Main Results:

  • LIF treatment induced rapid, transient phosphorylation of the LIF receptor.
  • Phosphorylation of JAK1 and, to a lesser extent, JAK2 was observed.
  • STAT1 and, to a lesser degree, STAT3 phosphorylation occurred in response to LIF.
  • Phosphorylated STAT1 proteins showed increased DNA binding affinity.

Conclusions:

  • LIF-induced signaling in osteoblasts involves the JAK/STAT pathway.
  • Specific JAK (JAK1, JAK2) and STAT (STAT1, STAT3) members mediate LIF's effects on bone cells.
  • These findings elucidate a molecular mechanism for LIF's role in bone remodeling.

Related Concept Videos